The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis

Anaplastic lymphoma kinase (ALK) is a tyrosine kinase involved in neuronal and gut development. Initially discovered in T cell lymphoma, ALK is frequently affected in diverse cancers by oncogenic translocations. These translocations involve different fusion partners that facilitate multimerisation and autophosphorylation of ALK, resulting in a constitutively active tyrosine kinase with oncogenic potential. ALK fusion proteins are involved in diverse cellular signalling pathways, such as Ras/extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/Akt and Janus protein tyrosine kinase (JAK)/STAT. Furthermore, ALK is implicated in epigenetic regulation, including DNA methylation and miRNA expression, and an interaction with nuclear proteins has been described. Through these mechanisms, ALK fusion proteins enable a transcriptional programme that drives the pathogenesis of a range of ALK-related malignancies.

• Publication year

  2019

• Venue

  Cancers

• Publication date

  2019-07-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/cancers11081074PMID 31366041PMCID 6721376
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

  2018cited by this paper
• The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma

  2018cited by this paper
• GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.

  2018cited by this paper
• ALK in Neuroblastoma: Biological and Therapeutic Implications

  2018cited by this paper
• Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond

  2018cited by this paper
• Novel ALK fusion in anaplastic large cell lymphoma involving EEF1G, a subunit of the eukaryotic elongation factor-1 complex

  2017cited by this paper
• Dynamic intramolecular regulation of the histone chaperone nucleoplasmin controls histone binding and release

  2017cited by this paper
• The long non-coding RNA LINC01013 enhances invasion of human anaplastic large-cell lymphoma

  2017cited by this paper
• Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-dependent phosphorylation of signal transducer and activator of transcription 3 and oncogenesis in anaplastic large cell lymphoma.

  2017cited by this paper
• Effects of SMYD2‐mediated EML4‐ALK methylation on the signaling pathway and growth in non‐small‐cell lung cancer cells

  2017cited by this paper
• Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.

  2017cited by this paper
• The role of anaplastic lymphoma kinase in pediatric cancers

  2017cited by this paper
• The Truncated Isoform of the Receptor Tyrosine Kinase ALK Generated by Alternative Transcription Initiation (ALKATI) Induces Chromatin Structural Changes in the Nucleus in a Kinase Activity-Dependent Manner.

  2017cited by this paper
• Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer

  2017cited by this paper
• Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress

  2016cited by this paper
• Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent

  2016cited by this paper
• Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer

  2016cited by this paper
• Coupling an EML4-ALK–centric interactome with RNA interference identifies sensitizers to ALK inhibitors

  2016cited by this paper
• Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling

  2016influential reference
• Novel Long Non Coding RNA Blackmamba Is Associated to ALK- anaplastic Large Cell Lymphoma

  2016cited by this paper
• HSP90 as a novel molecular target in non-small-cell lung cancer

  2016cited by this paper
• Nucleophosmin: from structure and function to disease development

  2016influential reference
• Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients

  2016cited by this paper
• ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New Testing Algorithm

  2016cited by this paper
• Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency

  2015cited by this paper
• Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth.

  2015cited by this paper
• Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches

  2015cited by this paper
• Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain.

  2015influential reference
• Long noncoding RNA hotair mediated angiogenesis in nasopharyngeal carcinoma by direct and indirect signaling pathways

  2015cited by this paper
• Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation

  2015cited by this paper
• French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas

  2015cited by this paper
• microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers

  2015influential reference
• Novel ALK fusion partners in lung cancer.

  2015cited by this paper
• The role of AP-1 and epigenetics in ALCL.

  2015cited by this paper
• The origins of ALK translocations.

  2015cited by this paper
• Long Non-coding RNA ANRIL and Polycomb in Human Cancers and Cardiovascular Disease.

  2015cited by this paper
• Alternative transcription initiation leads to expression of a novel ALK isoform in cancer

  2015cited by this paper
• Comprehensive assessment of targetable alterations in lung adenocarcinoma samples with limited material using MSK-IMPACT, a clinical, hybrid capture-based, next-generation sequencing (NGS) assay.

  2015cited by this paper
• PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer.

  2014cited by this paper
• Transcriptional regulatory functions of nuclear long noncoding RNAs

  2014cited by this paper
• Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer

  2014cited by this paper
• Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain

  2014cited by this paper
• ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.

  2014cited by this paper
• The role of miR-150 in normal and malignant hematopoiesis

  2014cited by this paper
• MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma.

  2013influential reference
• Novel TRAF1‐ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma

  2013cited by this paper
• DNA methylation reprogramming in cancer: Does it act by re-configuring the binding landscape of Polycomb repressive complexes?

  2013cited by this paper
• Genome-wide epigenetic regulation of miRNAs in cancer.

  2013cited by this paper
• Long Noncoding RNAs: Past, Present, and Future

  2013cited by this paper
• Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

  2013cited by this paper
• DNA Methylation and Its Basic Function

  2013cited by this paper
• KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only

  2012cited by this paper
• Increased miR-708 Expression in NSCLC and Its Association with Poor Survival in Lung Adenocarcinoma from Never Smokers

  2012cited by this paper
• Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

  2012cited by this paper
• Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

  2012cited by this paper
• MicroRNA and cancer

  2012cited by this paper
• A Genomic Regulatory Element That Directs Assembly and Function of Immune-Specific AP-1–IRF Complexes

  2012cited by this paper
• Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

  2012cited by this paper
• Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.

  2012cited by this paper
• Discovery of ALK‐PTPN3 gene fusion from human non‐small cell lung carcinoma cell line using next generation RNA sequencing

  2012cited by this paper
• The STAT3-DNMT1 connection

  2012cited by this paper
• A Prospective PCR-Based Screening for the EML4-ALK Oncogene in Non–Small Cell Lung Cancer

  2012cited by this paper
• MicroRNAs are shaping the hematopoietic landscape

  2012cited by this paper
• A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK

  2012cited by this paper
• DNA methylation: superior or subordinate in the epigenetic hierarchy?

  2011cited by this paper
• Exon scanning by reverse transcriptase-polymerase chain reaction for detection of known and novel EML4-ALK fusion variants in non-small cell lung cancer.

  2011cited by this paper
• IL-2R common γ-chain is epigenetically silenced by nucleophosphin–anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK

  2011cited by this paper
• CpG islands and the regulation of transcription.

  2011cited by this paper
• Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis

  2011cited by this paper
• Knockdown of NPM1 by RNA Interference Inhibits Cells Proliferation and Induces Apoptosis in Leukemic Cell Line

  2011cited by this paper
• The multifunctional protein nucleophosmin (NPM1) is a human linker histone H1 chaperone.

  2011cited by this paper
• DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer

  2011cited by this paper
• miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma.

  2011cited by this paper
• MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells.

  2011cited by this paper
• Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.

  2010cited by this paper
• NPM1/B23: A Multifunctional Chaperone in Ribosome Biogenesis and Chromatin Remodeling

  2010cited by this paper
• The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model.

  2010cited by this paper
• Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK− anaplastic large-cell lymphoma

  2010influential reference
• Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex.

  2010cited by this paper
• A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry

  2010cited by this paper
• Expression analysis of EML4 in normal lung tissue and non-small cell lung cancer (NSCLC) in the absence and presence of chemotherapeutics.

  2010cited by this paper
• Linking DNA methylation and histone modification: patterns and paradigms

  2009cited by this paper
• NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells.

  2009cited by this paper
• KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

  2009cited by this paper
• miR-155 gene: a typical multifunctional microRNA.

  2009cited by this paper
• Nucleophosmin Blocks Mitochondrial Localization of p53 and Apoptosis*

  2009cited by this paper
• Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non–Small Cell Lung Cancers

  2009cited by this paper
• Lack of TNFα expression protects anaplastic lymphoma kinase-positive T-cell lymphoma (ALK+ TCL) cells from apoptosis

  2009cited by this paper
• A mouse model for EML4-ALK-positive lung cancer

  2008cited by this paper
• EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

  2008cited by this paper
• The anaplastic lymphoma kinase in the pathogenesis of cancer

  2008cited by this paper
• Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

  2008cited by this paper
• Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts

  2008cited by this paper
• Transcription Regulation of the rRNA Gene by a Multifunctional Nucleolar Protein, B23/Nucleophosmin, through Its Histone Chaperone Activity

  2008cited by this paper
• Epigenetic changes and suppression of the nuclear factor of activated T cell 1 (NFATC1) promoter in human lymphomas with defects in immunoreceptor signaling.

  2008cited by this paper
• Lysine 263 residue of NPM/B23 is essential for regulating ATP binding and B23 stability

  2008cited by this paper
• Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation

  2008cited by this paper
• Echinoderm microtubule-associated protein like protein 4, a member of the echinoderm microtubule-associated protein family, stabilizes microtubules.

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007influential reference
• NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma.

  2007cited by this paper

• NPM1 Mediates mRNA Sorting into Extracellular Vesicles via Specific RNA Motif Binding and Phase Separation.

  2026cites this paper
• Unraveling Resistance in Lung Cancer Immunotherapy: Clinical Milestones, Mechanistic Insights, and Future Strategies

  2025cites this paper
• Multiscale Computational and Pharmacophore-Based Screening of ALK Inhibitors with Experimental Validation

  2025cites this paper
• Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures.

  2025cites this paper
• Predicting ROS1 and ALK fusions in NSCLC from H&E slides with a two-step vision transformer approach

  2025cites this paper
• Aberrations in the glycosylation of receptor tyrosine kinases: A focus on lung adenocarcinoma

  2025cites this paper
• Design and molecular mechanism investigation of ALK inhibitors based on virtual screening and structural descriptor modeling

  2025cites this paper
• Plasma ALKAL2 levels are associated with coronary atherosclerosis in patients with type 2 diabetes mellitus

  2025cites this paper
• Identification, experimental validation, and computational evaluation of potential ALK inhibitors through hierarchical virtual screening

  2025cites this paper
• ALK-based dual inhibitors: Focus on recent development for non-small cell lung cancer therapy.

  2025cites this paper
• Molecular crosstalk between GPCR and receptor tyrosine-protein kinase in neuroblastoma: molecular mechanism and therapeutic implications

  2025cites this paper
• ALK-1 positive anaplastic large cell lymphoma in sickle cell trait: A case report and review of literature

  2025cites this paper
• An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors

  2025cites this paper
• Treating Hematological Malignancies With OR‐2100, an Orally Bioavailable Prodrug of Decitabine

  2025cites this paper
• ALKATI drives nuclear ALK expression in histiocytic neoplasms without ALK fusions.

  2025cites this paper
• mTOR in radiotherapy of lung cancer: Mechanisms of radiation resistance and therapeutic implications (Review)

  2025cites this paper
• Molecular Mechanisms and Treatment Strategies of ALK‐Positive Lung Cancer: A Beginner's Guide for Patients, Their Families and Carers

  2025cites this paper
• Myeloproliferative neoplasm harboring both monosomy 7 and an ALK/ROS1 fusion gene: Proposal for a new disease entity

  2024cites this paper
• Reprogramming tumor-associated macrophages: The role of MEK-STAT3 inhibition in lung cancer.

  2024cites this paper
• Acquired resistance to tyrosine kinase targeted therapy: mechanism and tackling strategies.

  2024cites this paper
• Brain Exposure to the Macrocyclic ALK Inhibitor Zotizalkib is Restricted by ABCB1, and Its Plasma Disposition is Affected by Mouse Carboxylesterase 1c.

  2024cites this paper
• Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions

  2024cites this paper
• Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?

  2024cites this paper
• Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft Model

  2024cites this paper
• Malignant Epithelioid Mesenchymal Neoplasm with FUS::CREM Gene Fusion Arising in the Tongue: A Case Report Detailing Clinicopathological, Imaging, and Molecular Features

  2024cites this paper
• Osteoblastoma of the thumb with a novel PRSS44::ALK fusion and literature review of osteoblastoma of hands and feet bones

  2024cites this paper
• HER3 overexpression: a predictive marker for poor prognosis in advanced ALK-positive non-small cell lung cancer treated with ALK inhibitors

  2024cites this paper
• Ruolo della funzione respiratoria in pneumologia

  2024cites this paper
• Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.

  2024cites this paper
• Drug resistance mechanism and reversal strategy in lung cancer immunotherapy

  2023cites this paper
• Comparative Efficacy of ALK Inhibitors for Treatment-Naïve ALK-Positive Advanced Non-Small Cell Lung Cancer with Central Nervous System Metastasis: A Network Meta-Analysis

  2023cites this paper
• ZYY-B-2, a novel ALK inhibitor, overcomes resistance to ceritinib by inhibiting P-gp function and induces apoptosis through mitochondrial pathway in ceritinib-resistant H2228 cells.

  2023cites this paper
• ALK-positive lung cancer: a moving target

  2023cites this paper
• Inter- and intratumoral proteomics and glycosaminoglycan characterization of ALK rearranged lung adenocarcinoma tissues: a pilot study

  2023cites this paper
• A Combination of Alectinib and DNA-Demethylating Agents Synergistically Inhibits Anaplastic-Lymphoma-Kinase-Positive Anaplastic Large-Cell Lymphoma Cell Proliferation

  2023influential citation
• Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion

  2023cites this paper
• ALK fusions in the pan-cancer setting: another tumor-agnostic target?

  2023cites this paper
• Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical

  2023cites this paper
• Case Report of CCDC149–ALK Fusion: A Novel Genetic Alteration and a Clinically Relevant Target in Metastatic Papillary Thyroid Carcinoma

  2022cites this paper
• A Need for More Molecular Profiling in Brain Metastases

  2022cites this paper
• ALK, NUT, and TRK Do Not Play Relevant Roles in Gastric Cancer—Results of an Immunohistochemical Study in a Large Series

  2022cites this paper
• Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment

  2022cites this paper
• Quantification of Minimal Disease by Digital PCR in ALK-Positive Anaplastic Large Cell Lymphoma: A Step towards Risk Stratification in International Trials?

  2022cites this paper
• ALK Translocation in ALK-Positive Mesenchymal Tumors.

  2022cites this paper
• NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis

  2022cites this paper
• Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management.

  2022cites this paper
• EML4-ALK fusion gene in non-small cell lung cancer

  2022cites this paper
• PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphoma

  2022cites this paper
• Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer

  2022cites this paper
• Molecular characterization of genomic breakpoints of ALK rearrangements in non‐small cell lung cancer

  2022cites this paper
• Primary Central Nervous System ALK-Negative Anaplastic Large Cell Lymphoma: A Case Report and Literature Review

  2022cites this paper
• Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition

  2021cites this paper
• BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL

  2021cites this paper
• A recent development of new therapeutic agents and novel drug targets for cancer treatment

  2021cites this paper
• Mature T- and NK-Cell Neoplasms

  2021cites this paper
• Fusion genes in gynecologic tumors: the occurrence, molecular mechanism and prospect for therapy

  2021cites this paper
• Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis

  2021cites this paper
• Anaplastic Lymphoma Kinase Positive Large B-cell Lymphoma Mimicking Metastatic Carcinoma of the Cervical Lymph Node from an Unknown Primary Lesion

  2021cites this paper
• Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches

  2021cites this paper
• Combining Radiation Therapy with ALK Inhibitors in Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer (NSCLC): A Clinical and Preclinical Overview

  2021cites this paper
• The Spectrum of Anaplastic Large‐cell Lymphoma

  2021cites this paper
• Personalized and targeted therapies

  2021cites this paper
• Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition

  2021cites this paper
• Case Report: RAB10-ALK: A Novel ALK Fusion in a Patient With Gastric Cancer

  2021cites this paper
• Gene Fusion Identification Using Anchor-Based Multiplex PCR and Next-Generation Sequencing.

  2021cites this paper
• STRN-ALK rearranged pediatric malignant peritoneal mesothelioma – Functional testing of 527 cancer drugs in patient-derived cancer cells

  2021influential citation
• NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target

  2021cites this paper
• Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer

  2021cites this paper
• Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL

  2021cites this paper
• Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer

  2021cites this paper
• Natural Compounds Targeting Major Signaling Pathways in Lung Cancer

  2021cites this paper
• Clinicopathological features and resistance mechanisms in HIP1‐ALK‐rearranged lung cancer: A multicenter study

  2021cites this paper
• Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis

  2020cites this paper
• Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells

  2020cites this paper
• Salivary Secretory Carcinoma Harboring a Novel ALK Fusion

  2020cites this paper
• Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma.

  2020cites this paper
• Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine

  2020cites this paper
• ALK Inhibitors-Induced M Phase Delay Contributes to the Suppression of Cell Proliferation

  2020cites this paper
• Requirement of DNMT1 to orchestrate epigenomic reprogramming during NPM-ALK driven T cell lymphomagenesis

  2020cites this paper
• Requirement of DNMT1 to orchestrate epigenomic reprogramming for NPM-ALK–driven lymphomagenesis

  2020cites this paper
• Tyrosine Kinase Receptors in Oncology

  2020cites this paper
• Chromosome structural variation in tumorigenesis: mechanisms of formation and carcinogenesis

  2020cites this paper
• A JAK/STAT-Mediated Inflammatory Signaling Cascade Drives Oncogenesis In AF10-Rearranged AML

  2020cites this paper
• ALCL by any other name: the many facets of anaplastic large cell lymphoma.

  2019cites this paper
• STAT5A and STAT5B—Twins with Different Personalities in Hematopoiesis and Leukemia

  2019cites this paper
• Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond

  2018cites this paper